Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral orforglipron versus placebo in overweight adults at risk of obesity-related complications
jRCT2031260563Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in Overweight, Abdominal adiposity (ABCD), prediabetes and 1 more (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to onset of obesity related complications or class 1 obesity. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
orforglipron
03
Conditions
OverweightAbdominal adiposity (ABCD)prediabetesprehypertension
Beyond the preview
Go deeper on jRCT2031260563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260563.